SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4

Journal: Nature Communications

Published: 2018-12-19

DOI: 10.1038/s41467-018-07620-0

Affiliations: 26

Authors: 35

Go to article
Institutions FC
Sanger Institute Haematological Cancer Genetics Group, United Kingdom (UK) 0.22
Exonate, United Kingdom (UK) 0.07
Helmholtz Zentrum München - German Research Center for Environmental Health (HMGU), Germany 0.07
School of Chemistry, UNSW, Australia 0.06
H3 Biomedicine Inc., United States of America (USA) 0.06
Wellcome Trust Genome Campus, United Kingdom (UK) 0.06
Department of Haematology, University of Cambridge, United Kingdom (UK) 0.06
Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, United Kingdom (UK) 0.04
Wellcome Trust/Cancer Research UK Gurdon Institute (The Gurdon Institute), University of Cambridge, United Kingdom (UK) 0.04
Sanger Institute Cellular Genetics Programme, United Kingdom (UK) 0.04
Department of Pathology, University of Cambridge, United Kingdom (UK) 0.04
UK DRI at The University of Cambridge (UK DRI Cambridge), United Kingdom (UK) 0.03
Division of Cellular and Molecular Pathology, University of Cambridge, United Kingdom (UK) 0.03
School of Pharmacy and Biomedical Sciences, University of Portsmouth, United Kingdom (UK) 0.03
NIHR Cambridge Biomedical Research Centre (Cambridge BRC), United Kingdom (UK) 0.03
GlaxoSmithKline Medicines Research Centre, United Kingdom (UK) 0.03
Cambridge University Hospitals NHS Foundation Trust, United Kingdom (UK) 0.02
German Consortium of Translational Cancer Research (DKTK), Germany 0.02
School of Medicine, UoN, United Kingdom (UK) 0.01
Karaiskakio Foundation, Cyprus 0.01
Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, United Kingdom (UK) 0.01
European Bioinformatics Institute (EMBL-EBI), United Kingdom (UK) 0.01
Department of Pediatrics, LMU, Germany 0.01
TUM Center for Translational Cancer Research (TranslaTUM), Germany 0.01
TUM Department of Internal Medicine II (Gastroenterology), Germany 0.01
TUM Institute of Molecular Immunology and Experimental Oncology (IMI), Germany 0.01

Return